MAPT and neurodegenerative disease: Since recent clinical trials for neurodegenerative diseases have focused on targeting pathological tau aggregates,7 the in vivo identification of the presence of tau proteins could advance the development of anti‐tau therapies by enabling appropriate subject selection, early intervention, and assessment of target engagement.